Combination for advanced skin cancer extends survival compared with monotherapy
from Medical News Today
The combination of cobimetinib and Zelboraf (vemurafenib) has been shown to extend the lives of previously untreated patients with advanced skin cancer to nearly two years — an improvement of nearly five months more than the approved treatment, vemurafenib alone — according to new data from the coBRIM study presented at the Society for Melanoma Research annual meeting.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063